CMV serostatus reassessment within 6 months of transplant had 91.3% adherence, identifying a low seroconversion incidence of 1.6% in kidney transplant candidates.
What is the program adherence to CMV serostatus reassessment and the incidence of seroconversion in initially CMV seronegative kidney transplant candidates?
Program adherence to CMV serostatus reassessment within 6 months of kidney transplant was high, revealing a low incidence of seroconversion while on the waitlist.
Absolute Event Rate: 0% vs 0%
ABSTRACT Background Recipient cytomegalovirus (CMV) serostatus reassessment proximate to transplant for initially CMV seronegative patients is critical to guide post‐transplant CMV preventive strategies in kidney transplant recipients (KTR), since seroconversion during the long wait‐list time could lead to CMV serostatus misclassification. The feasibility and optimal timing of CMV serostatus reassessment and the incidence of seroconversion have not been systematically examined. Methods Program adherence to a guideline for CMV serology reassessment within 6 months of transplant among initially CMV seronegative adults undergoing a first kidney transplant between December 17, 2022 and December 17, 2024 was retrospectively assessed. The association of baseline and transplant factors with adherence was compared by chi‐square or Fisher's exact test ( p 0.05 for all variables). Seroconversion between listing and transplant occurred in two of 124 patients (1.6%), an incidence of 0.0043 per person‐year of follow‐up. Conclusion Program adherence to CMV serostatus reassessment within 6 months of transplant was high in a clinical setting and identified a low incidence of seroconversion.
Pama‐Ghuman et al. (Mon,) reported a other. CMV serostatus reassessment within 6 months of transplant had 91.3% adherence, identifying a low seroconversion incidence of 1.6% in kidney transplant candidates.